< Back to Article

APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts

Fig 3

Lifetime (to age 80–85 y) cumulative incidence curves, adjusting for competing risk of mortality, for mild cognitive impairment or dementia by baseline age and APOE-e4 dose.

Note that the strata shown are not independent (see text). MCI, mild cognitive impairment.

Fig 3